The four-year-old biotech raised about $75 million in a Series A round that involved nine venture capital firms.

Actithera, a radiopharmaceutical biotech pioneering precision radioligand therapies, has closed an oversubscribed Series A ...

BIO investing in unique radiopharmaceutical platform company, developing radioligands with prolonged tumour retention Series A was co-led by 4BIO Capital, founding investor M Ventures, Hadean Ventures ...

Actithera has secured $75.5 million in an oversubscribed Series A round to support the clinical development of its lead ...

Series A co-led by founding investor M Ventures and new lead investors Hadean Ventures, Sofinnova Partners, and 4BIO Capital with syndica ...

BIO investing in unique radiopharmaceutical platform company, developing radioligands with prolonged tumour retention ...